Iron dosing in kidney disease: inconsistency of evidence and clinical practice. - Wikidata - wikimedia - TriplyDB

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

http://www.wikidata.org/entity/Q35022235

about

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis Safety of intravenous iron in hemodialysis patients.Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients Impact of Oxidative Stress in Premature Aging and Iron Overload in Hemodialysis Patients.Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys Investigational therapies for renal disease-induced anemia.Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.

P2860

Q26752664-73C12232-66FC-4033-B254-DE6FF1994FE0 Q28547636-83727F27-16C0-4FC7-BE05-E2277D6AD31E Q30234981-6CABE502-57ED-4F64-8922-A5FD1EC3CEF4 Q37069943-58716E3A-B27F-42DC-B965-4F0017DF940E Q37348584-96D485C6-2E75-43C2-814D-93272472E044 Q37600377-B3642595-A55C-4772-9843-0532A1BF4D03 Q38819455-2420E32F-BDF9-43A3-9F9D-093E74C2409D Q38946879-50595105-7512-4379-8B2D-1D4BA0F2E05D Q53823548-F679F959-979B-4825-AF2B-E17D30E7F884

P2860

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

http://www.wikidata.org/entity/Q35022235

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

@ast

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

@en

type

label

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

@ast

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

@en

prefLabel

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

@ast

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

@en

P1433

Q35022235-8E11CABD-C54E-4C69-A0EE-3FDA5198FEF8

P1476

Q35022235-C2187FB2-DD9B-4307-879F-0B05764469B0

P2093

Q35022235-3B1619E1-2B78-489B-AA2E-D9CFE772C764

Q35022235-5056C092-E695-4D95-B1DD-ED5529B229DB

Q35022235-7942857D-F446-47AB-9E42-B5B0EBC18EC4

Q35022235-944E2FEB-82A9-45EC-9477-8A0444EE2F81

Q35022235-BC62FC38-2D27-4945-B0F3-860E6498EF0A

Q35022235-BF8DB13B-3A9C-412E-A74D-E2F041AFE8C5

P2860

Q35022235-084BD801-5A4F-4093-82BF-C32B1611984A

Q35022235-0B43A7C3-3108-4FF2-8178-8362E3DD236D

Q35022235-0CB6773A-0FA6-403B-B778-EFA691062D69

Q35022235-0D7DD836-E413-4195-8CE0-868FF87AC4EA

Q35022235-1008F0F7-AC14-4F97-A7C8-8658C0B05C6F

Q35022235-14D1DC2C-C32C-4024-9992-09DD8E7E4BD5

Q35022235-17700B4D-20FA-410B-A136-A0323BACD089

Q35022235-19999424-82BA-4020-B6C0-D0390B2F0E7F

Q35022235-1D564BBF-84EB-434F-B863-3EA6FBAE346C

Q35022235-21FD35E4-74BC-4606-B0BC-80E4E195BF64

P304

Q35022235-10002B1B-CABD-4BEC-A6AD-91527800EE82

P31

Q35022235-2E8C786E-41B1-40AA-84D7-8322387B5787

P356

Q35022235-D882258C-9976-45E9-9B1F-F76945B2F3BE

P407

Q35022235-63A0AA61-138B-4A95-B14A-8C23D4E07171

P433

Q35022235-26C9F18C-E57A-465D-810C-0474B6A5E499

P478

Q35022235-007830EE-8E82-41C1-ACA3-76AECA14CCEC

P577

Q35022235-DFF24C92-3920-4878-A089-2FABCFEAAE93

P698

Q35022235-D31614A9-779F-4F67-8B12-FF2A47342456

P932

Q35022235-35D18814-9A57-4417-9419-4BD6A08343DD

P356

P1433

Nephrology Dialysis Transplantation

P1476

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

@en

P2093

Adam E Gaweda

http://www.w3.org/2001/XMLSchema#string

Eliezer Rachmilewitz

http://www.w3.org/2001/XMLSchema#string

George R Aronoff

http://www.w3.org/2001/XMLSchema#string

Michael J Germain

http://www.w3.org/2001/XMLSchema#string

Yelena Z Ginzburg

http://www.w3.org/2001/XMLSchema#string

Yossi Chait

http://www.w3.org/2001/XMLSchema#string

P2860

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor

Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease

Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease

Beta-thalassemia

The ferritins: molecular properties, iron storage function and cellular regulation

Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System.

Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.

Platelet parameters in women with iron deficiency anemia.

Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.

P304

187-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFU104

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24821751

http://www.w3.org/2001/XMLSchema#string

P932

4309189

http://www.w3.org/2001/XMLSchema#string